Skip to main content
. 2009 Oct 13;21(4):884–894. doi: 10.1093/annonc/mdp377

Table 3.

Treatment-emergent AEs occurring in three or more patients irrespective of causality

Number of patients experiencing AE Study 1 AZD5438 dose (mg, q.i.d.)
Study 2 AZD5438 dose (mg, q.i.d.)
Study 3 AZD5438 dose (mg, q.i.d.)
10 (3) 20 (3) 40 (4) 60 (6) 90 (3) Total n (%) (19) 5 (3) 10 (3) 20 (3) 40 (8) Total n (%) (17) 2.5 (3) 5(3) 10 (5) 20 (11) 40 (6) Total n (%) (28)
Nausea 1 3 3a 4 2 13 (68) 1 2 3 7a 13 (76) 1 1 3 5 4 14 (50)
Vomiting 0 1 3a 4 3 11 (58) 1 0 2 4 7 (41) 1 0 4 4a 3 12 (43)
Diarrhoea 1 1 0 4a 1 7 (37) 0 0 1 3 4 (24) 1 0 0 1 2 4 (14)
Constipation 2 1 2a 1 0 6 (32) 0 1 1 3 5 (29) 1 0 2 3 0 6 (21)
Abdominal pain 0 0 0 2 1 3 (16) 0 0 0 3 3 (18)
Fatigue 1 1 1 1 2a 6 (32) 1 1 1 5 8 (47) 1 2 2 5 5a 15 (54)
Pyrexia 0 2 0 3 0 5 (26) 0 0 0 3 3 (18) 0 0 1 1 2 4 (14)
Nasopharyngitis 1 1 1 0 1 4 (21)
Anorexia 0 0 1 1 1 3 (16) 0 2 2 3 7 (41) 0 0 1 3a 1 5 (18)
Back pain 0 0 0 3a 0 3 (16) 1 0 1 1 3 (18)
Headache 1 0 2 0 2 5 (26) 1 0 1 1 3 (18) 0 0 1 2 1 4 (14)
Urinary retention 0 0 1 2 0 3 (16)
Dyspnoea 1 0 0 1a 1b 3 (16) 0 0 1a 2 2 5 (18)
Lethargy 1 1 2 1 5 (29)
Cough 1 0 0 3 4 (24) 1 0 1 1 0 3 (11)
Dyspepsia 1 0 1 1 3 (18)
Dehydration 0 0 0 2 1 3 (11)
Dizziness 0 1 0 2 0 3 (11)
Oedema 0 1 0 1a 1 3 (11)
a

All AEs were CTC grade 1 or 2 except for CTC grade 3 AEs (n = 1).

b

All AEs were CTC grade 1 or 2 except for a single CTC grade 4 AE.

AE, adverse event.